Checkpoint Therapeutics (NASDAQ:CKPT) Earns “Buy” Rating from D. Boral Capital

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $4.80 price target on the stock, down from their previous price target of $9.00. D. Boral Capital’s price objective would indicate a potential upside of 20.00% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital boosted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th.

Checkpoint Therapeutics Trading Up 0.5 %

CKPT opened at $4.00 on Monday. The stock has a 50-day moving average price of $3.13 and a 200-day moving average price of $3.10. Checkpoint Therapeutics has a 12-month low of $1.38 and a 12-month high of $4.50. The stock has a market capitalization of $195.33 million, a P/E ratio of -2.17 and a beta of 1.41.

Insider Buying and Selling at Checkpoint Therapeutics

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the completion of the transaction, the chief financial officer now owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This represents a 20.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO James F. Oliviero III sold 10,331 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. The trade was a 0.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 582,336 shares of company stock valued at $2,156,801 in the last 90 days. Insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its holdings in shares of Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after acquiring an additional 23,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after acquiring an additional 124,787 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock worth $291,000 after acquiring an additional 80,000 shares during the period. Walleye Capital LLC purchased a new position in shares of Checkpoint Therapeutics during the 3rd quarter worth approximately $148,000. Finally, Virtu Financial LLC purchased a new position in shares of Checkpoint Therapeutics during the 3rd quarter worth approximately $30,000. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.